Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, ...

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.

Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

In a busy reporting day for biotechs, Orthocell reports promising results of a follow-up study of its nerve repair device Remplir.

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti ... drug development and global strategy, but also brings new hopes to patients ...

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer ...

Stanford University researchers report the discovery of eight previously unknown genes that, when expressed in tobacco leaves, reconstitute the Taxol precursor baccatin III at levels matching its ...

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

The EMA has given a positive opinion for the exceptional circumstances authorization of Imreplys (sargramostim) to treat myelosuppression after acute radiation exposure.

A team of international researchers led by scientists at City of Hope®, one of the largest and most advanced cancer research ...